research News

ROCHESTER, Minn. — A new treatment is showing promise for people with high-risk smoldering multiple myeloma (SMM). This precancerous condition can progress to active multiple myeloma, a type of blood cancer. High-risk SMM carries a higher likelihood of progression. Results from a phase 3 clinical trial, published in the New England Journal...
Malaga, Spain – The scientist of the Faculty of Medicine of the University of Malaga José Luis Royo has coordinated a study that summarizes eight years of research and brings together 100 multidisciplinary specialists, identifying a mutation that alters Alzheimer’s disease progression. This work, published in Journal of Alzheimer’s Disease,...
NORWALK, Conn. — The Multiple Myeloma Research Foundation (MMRF) announced today a new publication on the CoMMpassSM study in Nature Genetics that defines distinct subtypes and identifies high-risk genetic markers of multiple myeloma. These CoMMpass data represent the largest and most complete clinical and molecular dataset in multiple myeloma. “Despite...
Cologne, Germany – The Federal Joint Committee (G-BA), the highest decision-making body in the German health care system, commissioned the Institute for Quality and Efficiency in Health Care (IQWiG) to assess a total of 10 drugs for the treatment of multiple sclerosis (MS): The immunomodulators cladribine, dimethyl fumarate, ozanimod, ponesimod,...
What’s the connection between Gaucher disease, a rare single gene disorder of metabolism that appears during childhood, and Parkinson’s disease, a common multifactorial disorder of the nervous system that occurs late in life? The answer lies in just a single gene (glucocerebrosidase or GBA), which encodes an enzyme required for...
BALTIMORE – Akers Biosciences, Inc. (Nasdaq: AKER), with its proposed merger partner MyMD Pharmaceuticals, Inc. (“MyMD”), a clinical stage pharmaceutical company committed to extending healthy lifespan by focusing on developing two therapeutic platforms, today announced new data from a study conducted by Eurofins Discovery Phenotypic Center of Excellence. MYMD-1 is...